Related Experiment Video
Updated: May 16, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients
Mónica Garzón-Ibáñez1, Roxana Reyes2,3, Miguel Ángel Molina-Vila2
1Pangaea Oncology, Hospital Universitario Dexeus, Barcelona, Spain. mogarzon@panoncology.com.
Abstract:
Although most mutations in Epidermal Growth Factor Receptor (EGFR) found in non-small cell lung cancer (NSCLC) patients are targetable drivers, exon 20 insertions (ex20ins) represent a distinct and heterogeneous subgroup with differences in treatment outcomes and prognosis. Next Generation Sequencing (NGS) testing has played a key role in identifying ex20ins and associated co-alterations, enhancing our understanding of the complex biology within this group. Furthermore, new molecules recently developed, some of them still under investigation, are shown promising results in the clinical management of ex20ins patients. This review aims to give an update of the landscape of EGFR ex20ins, focusing on their molecular and clinical implications as well as on new treatment strategies emerging in clinical trials.
Insights
Epidermal Growth Factor Receptor (EGFR) exon 20 insertions are a unique subgroup of non-small cell lung cancer. Next Generation Sequencing and emerging therapies are improving outcomes for these patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal Growth Factor Receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC).
- Exon 20 insertions (ex20ins) are a distinct, heterogeneous EGFR mutation subgroup with poor prognosis.
- Traditional EGFR inhibitors show limited efficacy against ex20ins.
Purpose of the Study:
- To review the molecular and clinical landscape of EGFR ex20ins in NSCLC.
- To highlight the role of Next Generation Sequencing (NGS) in identifying these mutations and co-alterations.
- To discuss emerging therapeutic strategies for ex20ins.
Main Methods:
- Literature review of studies on EGFR ex20ins in NSCLC.
- Analysis of Next Generation Sequencing data for mutation identification.
- Review of clinical trial data for novel treatment strategies.
Main Results:
- EGFR ex20ins exhibit unique molecular characteristics and clinical behavior.
- NGS is crucial for accurate diagnosis and understanding co-occurring alterations.
- New targeted therapies and investigational drugs show promise in clinical trials.
Conclusions:
- EGFR ex20ins represent a significant challenge in NSCLC management.
- Advancements in NGS and targeted therapies are transforming treatment approaches.
- Further research and clinical trials are essential to optimize patient care.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
